Novo Nordisk, the pharmaceutical giant, is standing by its new obesity drug CagriSema amid investor disappointment over its late-stage trial results. Despite losing $125 billion in market value, the company remains optimistic about the drug’s potential, indicating superior weight-loss performance compared to its predecessor, Wegovy.
About the Author
